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Abstract 
Malaria is one of the most significant parasitic diseases affecting mankind today, exceeding 200 
million annual cases worldwide
1
. This disease has been a serious issue due to developed 
resistance to commonly available antimalarial drugs including atovaquone and artemisinin
2
,
 
the 
most relevant modern treatment (figure 1.1). This project focuses on the preparation of 1,2,3,4-
tetrahydroacridones  (figure 1.2) that can be tested for their activity against P. falciparum isolates 
TM90-C2B (an atovaquone-resistant parasitic strain) and W2 (an atovaquone-susceptible 
parasite). In the past, studies have shown that endochins (4(1H)-quinolones)
 3
 and acridines 
(figure 1.1) have been found to exhibit antimalarial activity
4
. The research aims to create 
tetrahydroacridone derivatives as a hybrid of endochins and acridines by utilizing structure-
activity relationship (SAR) studies of the benzenoid ring of the 1,2,3,4-tetrahydroyacridone 
scaffold by following the Topliss operational scheme. 1,2,3,4-tetrahydroacridones  are generated 
through a linear synthesis that involves the cyclization of substituted anthranilic acids by 
refluxing in phosphorus oxychloride (POCl3) with cycloalkanones to produce various 9-chloro-
1,2,3,4-tetrahydrohydroacridines. Subsequent hydrolysis in acetic acid gives the respective 
1,2,3,4-tetrahydroacridone. Since 1,2,3,4-tetrahydroacridones  contain some similar structural 
properties to naphthoquinolone and ubiquinone
5
 (an important feature in the parasite’s energy 
generation), it is hypothesized that 1,2,3,4-tetrahydroacridones are potential inhibitors of the 
parasite’s respiration at the site of the bc1 complex. Once compounds are synthesized they are 
screened in vitro against blood stage P. falciparum. 
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Introduction 
In 1946, a series of 4(1H)-quinolone including endochin was discovered to be one of the first 
synthetic sets of compounds displaying antimalarial activity in avian models
6
. Likewise, 
acridines and acridine-based drugs have been known to confer antimalarial activity, since World 
War II, when the U.S. army took great strides to reduce causalities as a result of malaria
7
.
 
Mechanistic studies have shown that some acridine-based compounds work by interacting and 
binding to heme to prevent it from crystallizing. This fact is important since the parasite stores 
heme as a food source
8
. Therefore, it is hypothesized that 1,2,3,4-tetrahydroacridones  (THA) as 
a hybrid of 4(1H)-quinolones and acridines, could display good inhibition against atovaquone-
susceptible and atovaquone-resistant P. falciparum isolates W2 and TM90-C2B. The core part of 
endochin is similar to that of atovaquone, except, endochin contains an aliphatic heptyl chain at 
the 3-position while atovaquone has a bicyclic ring system in its place.  Since atovaquone was a 
potent inhibitor of P. falciparum activity in the past
9
, and atovaquone has similar structural 
properties to endochin and ubiquinone (figure 1.1), incorporation of these features to the THA 
scaffold were envisioned as being the starting point for a structure activity relationship (SAR) as 
potential antimalarial agents (figure 1.3).  
 
N
acridine
O
O
HO
atovaquone
N
H
O
O
endochine
Cl  
Figure 1.1: Structure of existing antimalarial agents: atovaquone,  endochin,  and acridine.  
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Figure 1.2: Structure of ubiquinone (left) and napthoquinone (right). Ubiquinone is a crucial component in the 
electron transport chain of the mitochondria since it facilitates the generation of energy. 1,4-napthoquinone 
derivatives are chemotypes that are known for their anti-bacterial as well as for its antitumor properties.  
 
 
Figure 1.3: Structure of R-substituted 1,2,3,4-tetrahydroacridone, where R
1
=Cl-, MeO-, Me- and where X or Y= H- 
or Me- as a proposed antimalarial drug candidate. 
Plans to develop this hybrid came from pre-existing data which displayed acridine-based 
compounds as potent antimalarials. To further confirm the fact that THAs could be potent 
inhibitors of the mitochondrial bc1 complex, recent studies involving close relatives of 1,2,3,4- 
tetrahydroacridones (THA) such as acridinediones (differing from THAs primarily by a 
secondary ketone group) have shown inhibitory effects at low nanomolar concentration range. In 
fact, WR 249685, which is an acrididienone (figure 1.4), has been reported to have an inhibitory 
concentration that targets at half of the parasite activity (EC50 value) at about 3 nM
10
.
 
It has been 
reported that the hydrophobicity of the acridinedione’s benezoid ring confers strong inhibitory 
activity of the mitochondrial bc1 complex,
1
 which is crucial to the parasite’s energy generation. 
Although docking studies were not conducted in the Biagini study, it is suspected that the amine 
and ketone components of the benzenoid ring significantly contribute to the acridinedione’s 
inhibitory activity of parasite function by hydrogen bonding to certain amino acid residues in the 
enzyme’s binding site.   
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Figure 1.4: Structure of the S enantiomer of WR 249685. This compound is an acridinedione and is structurally 
similar to the tetrahydroacridone. 
In order to develop the library, the THA structure-activity relationships were determined by 
following a known procedure. The Topliss operational scheme
11
 is followed by synthesizing 
different analogs containing electron withdrawing or donating functional groups such as Cl-, F-, 
NO2-, Me-, and MeO- and comparing biological activity to the unsubstituted molecule of 
interest.  
 
Figure 1.5: Topliss operational scheme for aromatic substituents. As shown by the scheme, a Cl– substituent is 
first synthesized on the core compound (the THA) at the 4
th
 position or R
4
 of the benezoid ring. Different 
substituents are created according to the activity of the Cl– substituent at R4.  If  Cl– at R4 displays equal (E) activity 
to an unsubstituted THA, then the next step would be to add a –Me functional group to the core THA to test if this 
functional group has equal (E), more (M), or (L) less activity than the previous compound synthesized.  As a result, 
the THA library was expanded using this scheme. 
This stepwise schematic allows for researchers to determine how helpful the functional groups 
are in relation to the parent molecule’s activity.  The 1,2,3,4-tetrahydroacridones  containing 
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different substituent groups are tested in vitro to determine if they would have an effect on 
atovaquone-susceptible and atovaquone-resistant P. falciparum isolates W2 and  TMC2B90, 
respectively.  
Results & Discussion 
Chemistry: The structure-activity relationship (SAR) began with the generation of 1,2,3,4-
tetrahydroacridone compounds employing commercially available anthranilic acid and various 
cycloalkanones, where R
1-4
 = H-, Cl-, Me-, or MeO-, and X,Y could be H- or Me-. Compounds 
(1a-12a, 1b-12b, 1c-12c, 5d-6d) synthesized by this POCl3 method faced harsh acidic 
conditions. However, no regioisomers were created through this route, as the intermediate 
enamine formed in the reaction can only form one product (Scheme 1). 
Scheme 1. POCl3 reaction using commercially available anthranilic acids. 
OH
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X
X
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Y
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Y
Y
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An intermediate 9-chloro-1,2,3,4-tetrahydroacridone was isolated via flash chromatography and 
then hydrolyzed via acetic acid in a sealed tube at 200
o
C which furnished the various 1,2,3,4-
tetrahydroacridone. These crude compounds were collected via filtration and then further 
purified via recrystallization from pyridine.  
In the following scheme, anilines were used as an alternative (due to unavailable anthranilic 
acids), from which THAs (1d-4d) could be produced using a Conrad-Limpach cyclization 
Luong  11 
 
 
(Scheme 2). Aniline is refluxed at 110
◦
C with ethyl 2-oxocyclohexanecarboxylate, acetic acid, 
and benzene for 24 hours.  The crude material is then refluxed in biphenyl ether to attain the 
respective substituted THA. Molecules produced by this scheme produce regioisomers when 
meta-substituted anilines are used. 
Scheme 2. Conrad-Limpach Reaction using commercially available anilines. 
 
Furthermore, based on results in another ongoing project in the Manetsch laboratory, 4-chloro-3-
methoxyaniline was desired as a precursor to 7-chloro-6-methoxy-1,2,3,4-tetrahydroacridin-
9(10H)-one (7d). In the scheme below, 3-methoxy-4-chloroaniline was first prepared from 2,5-
dichloroanisole using sodium amide generated in situ. The aniline was then taken to the THA 
following the same Conrad-Limpach protocol (Scheme 3).  
Scheme 3. Sodamide reaction using Conrad-Limpach type reactions. 
Cl
O Cl
Na
-40oC
NH3 (l)
Cl
O NH2 N
H
O
O
Cl
O
i)
ii) Ph2O; reflux
2600C
AcOH, Benzene
Dean-Stark
 
All of the THAs were fully characterized including: 
1
H NMR (figures 1.6-1.14), 
13
C NMR 
(figures 1.15-1.22), melting point, HRMS (High Resolution Mass Spectroscopy). Upon 
determination of purity >95%, the compounds were sent to Dr. Kyle’s laboratory for in vitro 
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testing against the two different strains W2 (atovaquone-susceptible) and TM90-C2B 
(atovaquone-resistant). The compounds were further tested for toxicity against a macrophage 
assay, a J774 strain.  
Structure-Activity Relationship (R
1-4
, X, Y). 
 
Figure 1.6 THA Scaffold: This scaffold depicts the THA blueprint for which different substituents (Cl-, MeO-, Me-
) are attached at R
1-4
 positions. X,Y can be H- or Me-. 
The goal of this structure activity relationship is to gain insight to the types and on the positions 
of substituents that would give the most favorable drug-parasite interaction at the lowest 
inhibitory concentrations. This interaction is analyzed by measuring the drug’s EC50 against the 
parasite isolates. EC50 is required concentration induces a response halfway between the baseline 
and the maximum concentration after some specified exposure time. In other words, a drug’s 
EC50 allows for analysis of its potency. It is crucial that the drug shows interaction with both the 
atovaquone-susceptible and the atovaquone-resistant parasite isolates at small concentration 
ranges. If the THA only inhibits one of the susceptible or resistant parasite isolates, it signifies 
that either the drug is not that potent or that there is an increased possibility for drug resistance 
against malaria. For instance, if the drug candidate works well against the atovaquone- 
susceptible strain (W2), it does not mean that it will work well against the resistant strain 
(TM90-C2B). If the drug candidate can inhibit both the susceptible and resistant strain at low 
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concentration ranges, it will be a prime candidate for further studies. A drug candidate’s 
resistance index also provides another way to measure its potency. In order for a drug to be 
considered potent, its resistance index (or RI) should be equal to or less than 3. A drug’s 
resistance index is the ratio between the two parasite isolates’ EC50s. A ratio of 3 or less is a 
good indicator that the drug is working to impair parasite activity while not inducing chemical 
resistance. Thus, the smaller and the closer the EC50 values are, the smaller the EC50 ratio will 
be, and the more potent the drug is. The following tables (1.1-1.4) represent the SAR that was 
undertaken synthetically to determine which compounds would exhibit the best of these 
qualities.  
R1
Cl
H
H
H
Cl
H
H
H
Cl
H
H
H
R2
H
Cl
H
H
H
Cl
H
H
H
Cl
H
H
R3
H
H
Cl
H
H
H
Cl
H
H
H
Cl
H
R4
H
H
H
Cl
H
H
H
Cl
H
H
H
Cl
X1
H
H
H
H
Me
Me
Me
Me
H
H
H
H
Y1
H
H
H
H
H
H
H
H
Me
Me
Me
Me
EC(50) W2(nM)
1
1354
137
99
368
6702
1080
215
2994
4673
240
256
373
EC(50) TM90-C2B(nM)
1
10698
122
63
447
9551
645
538
5326
4726
829
117
599
Cmpd1
1a
2a
3a
4a
5a
6a
7a
8a
9a
10a
11a
12a
RI (W2/TM90-C2B)1
0.127
1.123
1.571
0.823
0.701
1.674
0.400
0.562
0.989
0.290
2.188
0.623
RI (TM90-C2B/W2)1
7.901
0.891
0.636
1.215
1.425
0.597
2.502
1.779
1.011
3.454
0.457
1.601
Table 1.1: Structure Activity Relationship with Cl–, X, and Y. 
Table 1.1 shows that there is a relationship between the Cl- functional group and the THA at 
certain positions. EC50 values are the lowest for W2 and TM90-C2B when Cl- is positioned at R
3
 
and R
2
, where X, Y= H. Strong results were obtained when R
3
 is Cl-substituted, W2 is inhibited 
at 99 nM while TM90-C2B is inhibited at 66 nM. In comparision, when Cl- is attached at R
2
 
(where X or Y= Me-), the inhibitory effect of the THA is not as strong. When Cl- is a substituent 
at R
2
, W2 is inhibited at 137nM, while TM90-C2B is inhibited at 122 nM. RI ratios for both 
compounds 2a and 3a are under 3, which support the fact that both compounds are potent against 
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both parasite isolates. Cl- alone works as a great substituent for the THA because of the 
inductive and resonance effects respectively. First, halogens, in particular, are highly 
electronegative and they withdraw electrons through the inductive effect. With Cl-, the inductive 
effect withdraws electron density through the sigma bond that connects the substituent to the 
benzenoid ring.
12
 In addition, Cl- can also donate nonbonding electrons back to the benzenoid 
ring due to resonance effects. As a result, Cl- exhibits both electron withdrawing and electron 
donating properties 
12
. Based on this fact and on the EC50 results displayed in table 1.1, it was 
hypothesized that the Cl- substituent’s dual electron withdrawing and donating properties best 
contributed to the THAs inhibitory action against the parasite isolates at the R
2
 and R
3
 positions. 
Thus, compounds 2a and 3a were observed to hold the best effective concentrations and are the 
most potent out of this particular data group.  
R1
Me
H
H
H
Me
H
H
H
Me
H
H
H
R2
H
Me
H
H
H
Me
H
H
H
Me
H
H
R3
H
H
Me
H
H
H
Me
H
H
H
Me
H
R4
H
H
H
Me
H
H
H
Me
H
H
H
Me
X1
H
H
H
H
Me
Me
Me
Me
H
H
H
H
Y1
H
H
H
H
H
H
H
H
Me
Me
Me
Me
EC(50) W2(nM)
1
2203
150
449
6248
2367
355
587
10359
791
166
474
3017
EC(50) TM90-C2B(nM)
1
889
152
656
4575
1755
112
319
10359
531
1982
2184
4132
Cmpd1
1b
2b
3b
4b
5b
6b
7b
8b
9b
10b
11b
12b
RI (W2/TM90-C2B)1
2.478
0.987
0.684
1.366
1.349
3.170
1.840
1.000
1.490
0.084
0.2170
0.7302
RI (W2/TM90-C2B)1
0.4035
1.013
1.461
0.732
0.741
0.315
0.543
1.000
0.671
11.94
4.608
1.370
 
Table 1.2: Structure Activity Relationship with Me–, X, and Y. 
Out of this data set, the lowest EC50 values result when R
2
 is Me- and when X, Y are H-. EC50 
values of 150 nM for W2 and 152 nM for TM90-C2B are observed for this compound. 
Compound 6b differs from compound 2b by containing dimethyls at the X positions. When 6b is 
compared against EC50 values from compound 2b, it is observed that compound 6b does not 
work well on the atovaquone-susceptible strain. As a result, it could be inferred that the dimethyl 
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groups on compound 6b may hinder some sort of binding interaction between parasite and the 
drugs and are not very useful functional groups in the optimization of THAs. Like the Cl-
substituted THAs, when X or Y all contain dimethyl functional groups, inhibitory concentration 
only decreases by a little when compared to the normal, unsubstituted THA (table 1.4, 1d). The 
significance of this result is that dimethyls do not increase the compound’s inhibitory effect 
against the parasite isolates and does not optimize the drug candidate at all. From this data set, it 
is believed that only the inductive electron donating effects from Me- substituted at the R
2
 
position generated an effective inhibitory action against the parasite isolates. Adding dimethyls 
to this compound decreased effective inhibitory action. 
R
1
MeO
H
H
H
MeO
H
H
H
MeO
H
H
H
R
2
H
MeO
H
H
H
MeO
H
H
H
MeO
H
H
R
3
H
H
MeO
H
H
H
MeO
H
H
H
MeO
H
R
4
H
H
H
MeO
H
H
H
MeO
H
H
H
MeO
X
1
H
H
H
H
Me
Me
Me
Me
H
H
H
H
Y
1
H
H
H
H
H
H
H
H
Me
Me
Me
Me
EC(50) W2(nM)
1
4771
90
2443
t.b.d.
6538
8404
9715
9715
1991
54
8404
9715
EC(50) TM90-C2B(nM)
1
4567
99
2528
t.b.d.
2490
9715
9715
4104
620
175
9715
4103
Cmpd1
1c
2c
3c
4c
5c
6c
7c
8c
9c
10c
11c
12c
RI (W2/TM90-C2B)
1
1.045
0.909
0.966
t.b.d.
2.625
0.865
1.000
2.367
3.211
0.3086
0.8651
2.368
RI (TM90-C2B/ W2)
1
0.957
1.100
1.034
t.b.d.
0.381
1.156
1.000
0.422
0.311
3.240
1.156
0.422
 
Table 1.3: Structure Activity Relationship with MeO–, X, and Y. 
Like the previously aforementioned Me- substituted THAs, methoxy (MeO-) substituted THAs 
displayed the lowest EC50 values (90 nM for W2 and 99 nM for TM90-C2B) when MeO- is in 
the R
2
 position and when X, Y are all H-, However, when the MeO- substituent is placed at the 
R
2
 position, and when X, Y are solely H-, this compound (2c) inhibits the parasites more 
effectively than when X or Y is dimethylated (compounds 6c and 10c). The increase in EC50 
value indicates that dimethyl substituents did not produce any increased activity. The presence of 
the dimethyls at X or Y positions did not enhance inhibitory action. Thus, the dimethyls were 
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found to be of little significance in further development of the THA compound. MeO- exhibited 
more inhibitory activity at the R
2
 position than at any other position. Consequently, it could be 
said that at the R
2
 position, the MeO- substituent’s inductive electron donating effects generated 
effective inhibitory action against the parasite isolates. 
R1
H
H
H
F
H
H
H
R2
H
NO2
H
H
H
H
MeO
R3
H
H
NO2
H
H
H
Cl
R4
H
H
H
H
H
H
H
X1
H
H
H
H
Me
H
H
Y1
H
H
H
H
H
Me
H
EC(50) W2(nM)
1
1218
1051
3162
536
1866
421
31
           EC(50) TMC2B90(nM)
1
853
959
379
2914
335
295
24
Cmpd1
1d
2d
3d
4d
5d
6d
7d
RI (W2/ TMC2B90)1
1.423
1.096
8.343
0.184
5.570
1.427
1.292
RI W2/ TMC2B901
0.700
0.913
0.120
5.437
0.180
0.701
0.774
 
Table 1.4: Miscellaneous Structure Activity Relationship with NO2-, F-, and H- substituted at R
1-4
, and with X, Y as 
H or Me. Compounds 1d, 5d-6d, were synthesized via Scheme 1. Compounds 2d-4d were produced by Scheme 2. 
Compound 7d was created using Scheme 3.  
Based on the findings in table 1.4, it is further hypothesized that electron withdrawing 
substituents such as NO2-, F- would have little to no effect on optimizing the THA inhibition 
against parasite activity when they are substituted at R
1-4
. It is believed that the NO2- and F- 
functional groups do not contribute as much inhibitory action as Cl- groups do, due to 
differences in structural properties and electronic properties. Structually, NO2- is larger and 
bulkier than Cl- , whereas F- is smaller in size than Cl-. This information is helpful in deciding 
what other electron withdrawing substituents work best to enhance THA activity. It can be seen 
from the data that the best electron withdrawing substituent cannot be too big or too small 
because it will affect the THAs ability to effectively inhibit parasite activity.                                               
Electronic properties also play an important role in understanding why the F- and NO2- 
functional groups are have less of an inhibitory effect than the Cl- substituent against parasite 
activity. Differences in electronic properties are governed by the mesomeric or resonance effect. 
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The resonance effect explains how different functional groups can be electron withdrawing, 
donating, or both based on the appropriate resonance structures.  Since it is known that Cl– is 
electron withdrawing, and slightly electron donating
12
, it is believed that the Cl- substituent 
confers some push-pull effect to the aromatic portion of the THA. In comparison to Cl-, NO2- is 
solely an electron withdrawing or pulling agent and does not contribute to a dual electronic effect 
like Cl-. Rather, NO2- tends to hold on to the resonating electrons contributed by the aromatic 
regions of the THA. Similarly, the F- substituent contributes more to an electron withdrawing 
effect since it is more electronegative than Cl- and tends to hold on to its electrons more. F- and 
NO2- have similar but varied withdrawing effects on the THA, but do not display of strong of an 
inhibitory effect as the Cl- functional group.  Therefore the F
-
 and NO2 groups at R 2 and R3 do 
not contribute to optimizing the THA compound. 
Additionally, it was thought that the normal, unsubstituted THA (1d) would have a lesser or an 
equal inhibitory effect against parasite activity than the F- and NO2- groups. The reason is 
because the unsubstituted THA has no substituents to allow for tuning of activities that might 
enhance inhibition against parasite activity. As results show, the THA depends on both electron 
withdrawing and donating groups to improve its inhibitory effects against parasite activity. In 
this miscellaneous group of compounds (Table 1.4), 7-chloro-6-methoxy-1,2,3,4-
tetrahydroacridin-9(10H)-one (7d) displayed the best inhibitory activity (31 nM for W2 and 24 
nM for TM90-C2B). Since Cl
-
 and MeO
-
 work well individually, it was believed if they were put 
together, they would further enhance the inhibitory effect against parasite isolates W2 and 
TM90-C2B. Individually, compounds 3d (R
3
= NO2), 4d (R
1
=F), 5d (R
1-4
=H, X=Me), 6d (R=H, 
Y=Me) were not as active as 7d. In fact, it took medium to high concentrations of the respective 
F- and NO2-substituted THAs to inhibit one or both of the parasite isolates W2 and TM90-C2B’s 
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activities. Similarly, unsubstituted THAs with Me- at X or Y positions also required great 
inhibitory concentrations to effectively decrease parasite activity. Resistance indices for 
compounds 3d (RI: 8.34), 4d (RI: 5.44), 5d (RI: 5.5) were greater than 3, which support the fact 
that these THAs, in particular, are not effective against atovaquone-susceptible and atovaquone-
resistant parasite isolates W2 and TM90-C2B.  
Conclusions. The eight most active compounds generated by following the Topliss series are 
shown below (table 1.5). Eight listed molecules (2a, 3a, 11a, 2c, 6c,10c, 2b, 6b)  except for  7-
chloro-6-methoxy-1,2,3,4,-tetrahydroacridin-9(10H)-one, were prepared by POCl3 acid catalyzed 
cyclizations of substituted anthranilic acids with various cycloalkanones (scheme 1) followed by 
acetic acid hydrolysis. The 7-chloro-6-methoxy-1,2,3,4,-tetrahydroacridin-9(10H)-one is 
synthesized by a synthetic aniline generated via a sodamide reaction which was then further 
subjected to Conrad Limpach conditions according to Scheme 3. Figures 1.6-1.14 show the 
respective 
1
H MNR of the eight best compounds. Figures 1.15-1.22 show the respective 
13
C 
NMR spectra. 
N
H
O
O N
H
O
O
2c
EC50 (W2): 90 nM
EC50 (C2B90): 99 nM
10c
EC50 (W2): 54 nM
EC50 (C2B90): 175 nM
N
H
O
N
H
O
2b
EC50 (W2) : 150 nM
EC50 (C2B90): 152 nM
6b
EC50 (W2): 355 nM
EC50 (C2B90): 122 nM
N
H
O
7d
EC50 (W2): 31 nM
EC50 (C2B90): 24 nM
N
H
O
Cl N
H
O
Cl
N
H
O
Cl
2a
EC50 (W2): 137 nM
EC50 (C2B90): 122 nM
3a
EC50 (W2): 99 nM
EC50 (C2B90):63 nM
11a
EC50 (W2): 256 nM
EC50 (C2B90): 117 nM
Cl
O
 
Table 1.5: Molecules with the greatest inhibitory activities against W2 and TM90-C2B. 
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The MeO- and the Cl- substituents at R
2
 and at R
3
 respectively had the best structural activity out 
of four possible positions. When the ortho R
2
 and R
3
 positions are filled by MeO– and Cl– 
respectively, even lower EC50 values results for W2 (31 nM) and TMC2B90 (24 nM). This 
compound is the best product so far since it displayed the greatest activity against atovaquone-
resistant TMCB90and atovaquone-susceptible W2 parasite isolates. This action is believed to be 
due to the mesomeric or resonance effect displayed by both the Cl– and MeO– functional groups. 
It was hypothesized that when these substituents were combined, an optimal THA could be 
created to inhibit the parasite isolates TMC2B90 and W2’s activity more effectively. The 
hypothesis was confirmed to be correct. The THA was shown to have a synergistic effect in 
activity when R
2
 = MeO- and R
3
 = Cl-. The fact that the MeO– functional group acts as the 
electron donating agent and the Cl– substituent works simultaneously as both an electron 
withdrawing and donating agent most likely contributes to the THA’s synergistic effect. Without 
the electron pushing and pulling synergistic effect created by these two substituents, a higher 
inhibitory concentration would have to be used to inhibit 50% of the activity displayed by 
atovaquone-susceptible W2 and atovaquone-resistant TMC2B90 parasite isolates. When these 
substituted THAs are paired with dimethyl groups at X and Y, the inhibitory activity of the THA 
is not as great as unsubstituted X and Y THAs. This event reveals that dimethyl substitutents are 
not necessary for inhibiting parasite activity. In addition, it is found that positions R
1 
and R
4
 were 
less important in terms of activity as compared to positions R
2
 and R
3
. Di-substituted as well as 
aryl substituted (R
2
 and R
3
) THAs are in preparation for further studies. 
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Experimental 
Materials. All Cl-, MeO-, Me- substituted anthranilic acids and substituted anilines, 
cycloalkanones, carboxylates and all solvents and reagents (POCl3, biphenyl ether, AcOH, 
NH4OH, NH3, DMF, pyridine) were purchased from Sigma Aldrich. Seal tubes and Dean-Stark 
were purchased from ChemGlass. 
1,2,3,4-Tetrahydroacridone Synthesis.  
General Procedure A: 1,2,3,4-Tetrahydroacridone synthesized via commercially available 
anthranilic  acid. 500 mg of substituted anthranilic acid (where R= Cl-, MeO-, Me-) are 
refluxed with a 1.1 equivalence of cyclohexanone in 2-3 mL of 1.2 M POCl3 for 2 hours in 
100
◦
C. After 2 hours of refluxing, the reaction is allowed to cool for 5 minutes before a Thin 
Layer Chromatography (TLC) is conducted to determine if the reaction is completed. A liquid 
chromatography mass spectroscopy (LC-MS) test is also taken to ensure that the right product is 
obtained and that all starting materials were converted to product. After confirming that the 
correct product is obtained, the reaction is quenched with 20mL of chloroform and ice water, and 
about 10mL of NH4OH to neutralize the acidic reaction. Litmus paper is used to confirm that the 
reaction is neutralized to a pH of 7-9. Afterwards, the organic layer is extracted via separatory 
funnel.  The aqueous layer is washed thrice with chloroform. The organic layers were combined 
and dried over Na2SO4 to ensure the complete removal of H2O.  Chloroform is removed via 
rotavap to afford the respective, crude 1,2,3,4-tetrahydroacridine intermediate. A dry load is 
prepared (for column chromatography) from the crude 1,2,3,4-tetrahydroacridine  by dissolving 
about 1g of silica gel with minimal amounts of chloroform. The product is purified via silica gel 
flash column chromatography in a hexane: ethyl acetate (15:1) solvent system. This system 
eventually progressed to 10:1 and 5:1 solvent systems until the product is eluted out. The column 
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is monitored by TLC to determine product elution. Once column chromatography is finished, 
and the product is obtained, TLC and LC-MS are conducted to verify the product and its purity. 
Fractions of the product are combined and concentrated down to leave the respective 1,2,3,4-
tetrahydroacridine intermediate. The intermediate is left to dry by high-vacuum overnight. Then, 
100 mg of the dried intermediate is hydrolyzed in AcOH at 200
◦
C for 2 hours to give the 
respective 1,2,3,4-tetrahydroacridone. After the reaction is confirmed by LC-MS and TLC to be 
completed, the reaction is allowed to cool for 5 minutes. H2O is used to quench the reaction by 
neutralizing the AcOH and the product precipitates out as a white solid. The precipitate is 
collected by vacuum filtration and is dried in the oven for at least 2-3 hours. LC-MS is taken to 
verify the product. The product is further purified through either column chromatography or 
through recrystallization in pyridine or DMF (N,N-dimethylformamide). After recrystallization, 
the crystalline product is collected via vacuum filtration and is washed with 50-60 mL of H2O to 
remove the remaining pyridine or DMF. The product is dried in the oven for 24 hours. Then, 10-
12 mg of dried, purified product is dissolved in DMSO-D6 and 
1
H NMR (figures 1.6-1.14) is 
taken to verify that the correct product is isolated. 
General Procedure B: 1,2,3,4-Tetrahydroacridone prepared via commercially available 
aniline. 1g of substituted aniline (where R= Cl-, MeO-, Me-) is refluxed with 1.5 equivalance of 
ethyl 2- oxocyclohexanecarboxylate, 2-5mL of benzene and a few drops of AcOH, and in a 
round bottom flask at 260
◦
C to generate the substituted ethyl 2-(phenylamino)cyclohex-1-
enecarboxylate intermediate. Benzene is added to the Dean-Stark trap to facilitate the removal of 
H2O from the reaction which forces the reaction to completion.  The reaction was left to reflux 
overnight. The reaction is allowed to cool for 5 minutes before conducting a TLC to determine if 
the reaction is completed. An LC-MS is also taken to ensure that all starting materials and 
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intermediate were converted to product. Benzene is removed by rotavap and the intermediate 
was dried over high-vacuum to provide the respective, leaving behind a crude substituted ethyl 
2-(phenylamino)cyclohex-1-enecarboxylate intermediate. About 8mL of Ph2O was used to reflux 
with the intermediate at 260
o
C for 2-5 hours. TLC and LC-MS are conducted to verify that all of 
the intermediate turned into the 1,2,3,4-tetrahydroacridone product. The reaction solution was 
rotavaped down to give the respective substituted 1,2,3,4-tetrahydroacridone. The product is left 
to dry by high-vacuum overnight. The product is further purified through recrystallization in 
pyridine or DMF (N,N-dimethylformamide). After recrystallization, the crystalline product is 
collected via vacuum filtration and is washed with 50-60 mL of H2O to remove the remaining 
pyridine or DMF. The product is dried in the oven for 24 hours. Then, 10-12 mg of dried, 
purified product is dissolved in d-DMSO (deuterated dimethyl sulfoxide) and 
1
H NMR is taken 
to verify that the correct product is isolated.  
General Procedure C:  7-chloro-6-methoxy-1,2,3,4,-Tetrahydroacridin-9(10H)-one created 
via sodamide reaction Conrad Limpach conditions. NaNH2 is generated in situ from sodium 
and liquid ammonia at -40
◦
C and is reacted with 1g of 2,5-dichloroanisole to generate 3-
methoxy-4-chloroaniline. After 2-5 hours, the reaction is checked for completion by TLC. An 
LC-MS is also taken to guarantee that all starting materials and intermediate were converted to 
product. The intermediate is left to dry by high-vacuum overnight. 100mg of the intermediate is 
refluxed with 1.1 equivalance of cyclohexanone, a few drops of AcOH, and 2-5mL benzene in a 
round bottom flask at 260
◦
C. Benzene was also put into the Dean-Stark trap to remove H2O to 
force the formation of the ethyl 2-(4-chloro-3-methoxyphenylamino)cyclohex-1-enecarboxylate 
intermediate to completion. Once TLC and LC-MS showed that the intermediate formed, about 
8mL of Ph2O was put into the reaction mixture, which was left to reflux at 260
◦
C overnight. TLC 
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and LC-MS are conducted to verify that all of the intermediate turned into the product. The 
reaction solution was rotavaped down to give the 7-chloro-6-methoxy-1,2,3,4,-tetrahydroacridin-
9(10H)-one. The product is left to dry by high-vacuum overnight. After the product is dried, it is 
further purified through recrystallization in pyridine or DMF (N,N-dimethylformamide). After 
recrystallization, the crystalline product is collected via vacuum filtration and is washed with 50-
60 mL of H2O to remove the remaining pyridine or DMF. The product is dried in the oven for 24 
hours. Then, 10-12 mg of dried, purified product is dissolved in d-DMSO and 
1
H NMR is taken 
to verify that the correct product is isolated (figure 1.21). 
Supplemental Information. 
6-chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (2a) . Compound was synthesized by POCl3 
reaction method (general procedure A). Solid was recrystallized from pyridine, filtered, and 
washed with copious amounts of H2O, dried, and then washed with cold ether and MeOH 
(methanol) to yield 63% of product. 
1H NMR (250 MHz, DMSO) δ 11.38 (s, 1H), 8.03 (d, J = 
8.6 Hz, 1H), 7.46 (s, J = 1.7 Hz, 1H), 7.22 (dd, J = 8.6, 1.8 Hz, 1H), 2.68 (t, J = 5.6 Hz, 2H), 2.41 
(t, J = 5.7 Hz, 2H), 1.84 – 1.60 (m, 4H). 13C NMR (101 MHz, DMSO) δ 175.38, 147.31, 139.92, 
135.51, 127.22, 122.37, 121.77, 116.39, 116.30, 27.11, 21.70, 21.55, 21.36. 
7-chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (3a).  Compound was generated by POCl3 
reaction method (general procedure A). After recrystallization in pyridine, product was washed 
with cold ether and MeOH (methanol) to afford 65%  yield.
1H NMR (400 MHz, DMSO) δ 11.51 
(s, 1H), 7.97 (d, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.50 (d, J = 8.8 Hz, 1H), 2.70 (t, J = 5.8 Hz, 2H), 
2.43 (t, J = 5.9 Hz, 2H), 1.73 (dd, J = 24.2, 5.1 Hz, 4H).
 13C NMR (101 MHz, DMSO) δ 174.70, 
147.32, 137.77, 131.04, 126.51, 124.07, 123.68, 119.83, 116.01, 27.10, 21.71, 21.63, 21.37. 
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7-chloro-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (11a).  Compound was produced 
by POCl3 reaction method (general procedure A). % Yield: 60%.
 1H NMR (400 MHz, DMSO) δ 
11.48 (s, 1H), 7.98 (d, J = 2.1 Hz, 1H), 7.60 (dd, J = 8.8, 2.1 Hz, 1H), 7.50 (d, J = 8.8 Hz, 1H), 
2.48 – 2.44 (m, 4H), 1.49 (t, J = 6.4 Hz, 2H), 0.98 (s, 6H). 13C NMR (101 MHz, DMSO) δ 
174.61, 146.61, 137.95, 131.07, 126.61, 124.13, 123.68, 119.88, 114.61, 40.54, 34.33, 28.99, 
27.54, 19.48. 
6-methoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (2c).  Compound was created by POCl3 
reaction (general procedure A). % Yield: 61%. 
1H NMR (400 MHz, DMSO) δ 11.38 (s, 1H), 
7.97 (d, J = 8.7 Hz, 1H), 6.85 (d, J = 10.0 Hz, 2H), 2.66 (d, J = 5.8 Hz, 2H), 2.41 (t, J = 5.4 Hz, 
2H), 1.76 – 1.65 (m, 4H). 
6-methoxy-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (10c).  Compound was 
generated by POCl3 reaction (general procedure A). % Yield: 75%. 
1
H NMR (400 MHz, DMSO) 
δ 11.10 (s, 1H), 7.94 (d, J = 9.3 Hz, 1H), 6.83 (s, 2H), 3.82 (s, 3H), 2.42 (d, J = 9.5 Hz, 4H), 1.48 
(t, J = 6.0 Hz, 2H), 0.98 (s, 6H).
 13C NMR (101 MHz, DMSO) δ 175.43, 161.32, 145.42, 141.07, 
126.62, 117.76, 113.57, 112.13, 98.20, 55.25, 40.52, 34.53, 28.98, 27.56, 19.36. 
6-methyl-1,2,3,4-tetrahydroacridin-9(10H)-one (2b).  Compound was made by POCl3 reaction 
(general procedure A). % Yield: 62%. 
1H NMR (250 MHz, DMSO) δ 11.17 (s, 1H), 7.92 (d, J = 
8.2 Hz, 1H), 7.21 (s, 1H), 7.03 (dd, J = 8.3, 1.1 Hz, 1H), 2.67 (t, J = 5.8 Hz, 2H), 2.45 – 2.35 (m, 
5H), 1.78 – 1.62 (m, 4H). 13C NMR (63 MHz, DMSO) δ 175.83, 146.44, 140.87, 139.45, 124.85, 
123.74, 121.29, 116.57, 115.26, 27.11, 21.91, 21.65, 21.53, 21.33. 
2,2,6-trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (6b).  Compound was synthesized by 
POCl3 reaction (general procedure A). % Yield: 62%. 
1H NMR (250 MHz, DMSO) δ 11.22 (s, 
1H), 7.92 (d, J = 8.2 Hz, 1H), 7.21 (s, 1H), 7.03 (dd, J = 8.3, 1.3 Hz, 1H), 2.69 (t, J = 6.5 Hz, 
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2H), 2.39 (s, 3H), 2.23 (s, 2H), 1.53 (t, J = 6.6 Hz, 2H), 0.96 (s, 6H).
 13
C NMR (101 MHz, 
DMSO) δ 176.07, 145.26, 140.84, 139.43, 124.82, 123.65, 121.20, 116.53, 114.28, 35.40, 33.91, 
28.51, 27.94, 24.60, 21.30. 
6-methoxy-7-chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (7d).  Compound was created by 
POCl3 reaction (general procedure A). % Yield: 70%. 
1H NMR (400 MHz, DMSO) δ 11.30 (s, 
1H), 7.95 (s, 1H), 6.98 (s, 1H), 3.92 (s, 3H), 2.64 (t, J = 5.8 Hz, 2H), 2.39 (t, J = 5.7 Hz, 2H), 
1.71 (dd, J = 24.5, 4.9 Hz, 5H). 
Instrumentation. All NMR spectra were obtained by using the 400 MHz Varian NMR 
spectrometer. All experimental samples were run in DMSO-d6. 
1
H NMR experiments are 
reported in parts per million (ppm) downfield of TMS and signals were measured relative to the 
reference signal for dimethylsulfoxide (2.50 ppm).  
13
C NMR spectra were reported in ppm 
relative to the reference signal for dimethylsulfoxide (39.5 ppm) with 
1
H decoupled observation. 
The following symbols used for 
1
H NMR peak analysis: chemical shift (δ ppm), multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet), integration and coupling constant 
(Hz). 
13
C NMR spectra were obtained at 101 MHz and peaks were reported in terms of chemical 
shift. All NMR data were analyzed by MestReNova Software version 5.3.2-4936. Agilent 
LC/MSD TOF system G3250AA was used to take High resolution mass spectra (HRMS). 
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Figure 1.7. 
1
H NMR spectrum of 6-chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 2a) synthesized 
by POCl3 reaction method.  
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Figure 1.8. 
1
H NMR spectrum of 7-chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 3a) generated by 
POCl3 reaction method.  
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Figure 1.9. 
1
H NMR spectrum of 7-chloro-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 11a) 
produced by POCl3 reaction method. 
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Figure 2.0. 
1
H NMR spectrum of 6-methoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 2c) created by 
POCl3 reaction. 
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Figure 2.1. 
1
H NMR spectrum of 6-methoxy-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 
10c) made by POCl3 reaction method. 
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Figure 2.2. 
1
H NMR spectrum of 6-methyl-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 2b) produced by 
POCl3 reaction method. 
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Figure 2.3. 
1
H NMR spectrum of 2,2,6-trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 6b) 
created by POCl3 reaction method. 
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Figure 2.4. 
1
H NMR spectrum of 6-methoxy-7-chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 7d) 
created by sodamide reaction method. 
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Figure 2.5.  
13
C  NMR spectrum of 6-chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 2a) synthesized 
by POCl3 reaction method. 
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Figure 2.6. 
13
C NMR spectrum of 7-chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 3a) generated by 
POCl3 reaction method. 
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Figure 2.7. 
13
C NMR spectrum of 7-chloro-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 
11a) produced by POCl3 reaction method. 
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Figure 2.8. 
13
C NMR spectrum of 6-methoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 2c) created by 
POCl3 reaction. 
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Figure 2.9. 
13
C NMR spectrum of 6-methoxy-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 
10c) made by POCl3 reaction method. 
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Figure 3.0. 
13
C NMR spectrum of 6-methoxy-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 
10c) generated through POCl3 reaction method. 
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Figure 3.1. 
13
C NMR spectrum of 6-methyl-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 2b) created by 
POCl3 reaction method. 
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Figure 3.2. 
13
C NMR spectrum of 2,2,6-trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (compound 6b) 
produced by POCl3 reaction method. 
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Appendix 
N
acridine
O
O
HO
atovaquone
N
H
O
O
endochine
Cl  
Figure 1.1: Structure of existing antimalarial drugs atovaquone, endochin, acridine. 
               
 
Figure 1.2: Structure of ubiquinone (left) and napthoquinone (right). Ubiquinone is a crucial component in the 
electron transport chain of the mitochondria since it facilitates in the generation of energy. 1,4- napthoquinone 
derivatives are chemotypes that are known for their anti-bacterial as well as for its antitumor properties.  
 
Figure 1.3: Structure of R-substituted 1,2,3,4-tetrahydroacridone, where R
1
=Cl-, MeO-, Me- and where X or Y= H- 
or Me- as a proposed antimalarial drug candidate. 
 
      
Figure 1.4: Structure of the S enanatiomer of WR 249685. This compound is an acridinedione and is structurally 
similar to the tetrahydroacridone. 
Luong  43 
 
 
References 
1 )Mazier, D., L. Renia, et al. "A pre-emptive strike against malaria's stealthy hepatic forms." 
Nat. Rev. Drug Discovery: Nature, (2009), 8(11): 854-864. 
2)Yeates, C. L., J. F. Batchelor, et al. "Synthesis and Structure-Activity Relationships of 4-
Pyridones as Potential Antimalarials." J. Med. Chem., (2008), 51(9): 2845-2852. 
3)Morgentin, R., G. Pasquet, et al. "Strategic studies in the syntheses of novel 6,7-substituted 
quinolones and 7- or 6-substituted 1,6- and 1,7-naphthyridones." Tetrahedron,. (2008),  
64(12): 2772-2782. 
4) Biagini, G. A., N. Fisher, et al. "Acridinediones: selective and potent inhibitors of the Malaria 
parasite mitochondrial bc1 complex." Mol. Pharmacol., (2008), 73(5): 1347-1355. 
5) Morgentin, R., G. Pasquet, et al. "Strategic studies in the syntheses of novel 6,7-substituted 
quinolones and 7- or 6-substituted 1,6- and 1,7-naphthyridones." Tetrahedron, (2008), 
64(12): 2772-2782. 
6)Salzer, Walter; Timmler, Helmut; Andersag, Hans. A  new type of compounds active against 
avian malaria. Chemische Berichte  (1948),  81  12-19. 
7) Greenwood, David.  “Conflicts  of  interest : the  genesis  of  synthetic   antimalarial   agents  
in  peace  and  war.‖ J. of Antimicrobial Chemotherapy (1995), 36(5),  857-72.  
8)Weissbuch, I. and L. Leiserowitz "Interplay Between Malaria, Crystalline Hemozoin 
Formation, and Antimalarial Drug Action and Design." Chem. Rev., (2008), 
(Washington, DC, U. S.) 108(11): 4899-4914. 
9) Yeates, C. L., J. F. Batchelor, et al. "Synthesis and Structure-Activity Relationships of 4-
Pyridones as Potential Antimalarials." J. Med. Chem., (2008), 51(9): 2845-2852. 
Luong  44 
 
 
10) Weissbuch, I. and L. Leiserowitz "Interplay Between Malaria, Crystalline Hemozoin 
Formation, and Antimalarial Drug Action and Design." Chem. Rev., (2008), 
(Washington, DC, U. S.) 108(11): 4899-4914. 
11)Topliss, J.G. ―Utilization of operational schemes for analog synthesis in drug design.‖ J. Med. 
Chem., (1972), 15, 1006-1011. 
12) Anon.   March 's Advanced  Organic   Chemistry :  Reactions ,  Mechanisms , and  Structure 
, 6th ed. by Michael B. Smith and Jerry  March.    Organic Process Research & 
Development  (2007),  11(5),  924.  
 
